For patients with severe kidney disease, a kidney transplant from a living donor can be life-saving. For this, both the recipient and the donor have to undergo an assessment process to determine eligibility. This can be a complicated process that involves lab tests, imaging, and appointments with kidney doctors and surgical team. Ideally, this process should be efficient, but for many recipients and donors, it can take over a year to complete. During this time, recipients and donors often do not know where they are in the process nor what they should be doing at a given point to complete the process. This can leave patients feeling confused, frustrated, and helpless, which can be a barrier to someone donating or receiving a kidney transplant. We want to make this experience and process better, and we need the help of patient donors and recipients (both those who are currently going through the process and those who have gone through it in the past) to tell us about their experiences - what went well, what didn't go so well, and what could be better. We're using Human-centred-design to make this happen. This is a creative process that, well, puts the human (that's YOU) in the centre of what we build and create, so you'd be working WITH us to make things better for patients like you in the future. Can you help?

cAPPricorn-1 is researching an investigational medication called mivelsiran (Pronounced my-VEL-sur-an) to see if it's safe and effective. Participating in this trial is a chance to contribute to CAA research. Mivelsiran is a type of medication called a RNAi therapeutic designed to lower the production of a specific protein called amyloid precusor protein (APP)in the brain. this reduction may potential reduce the harmful buildup of harmful amyloid proteins and the brain's blood vessels and potentially slow down the worsening of CAA. During the treatment period of cAPPricorn-1, you will have study visits about once every 3 months for a total of 12 visits over 2 years. With the optional 18-month open-label extension period, you would have an additional 5 study visits. There will also be a follow-up visit 1 year after the end of treatment, whether it be the double-blind treatment period or the open-label extension period.

Patients who present to the Foothills hospital with acute stroke symptoms receive a CT scan of their brain. If there is a blockage in one of the arteries, supplying blood to the brain and there is no hemorrhage, and if they are eligible, they receive standard stroke treatment, which is administration of a clot dissolving agent and repeat imaging of the brain to check if the clot is dissolved. Depending on the location of the clot, sometimes thrombectomy is also performed. During thrombectomy, the doctor makes a small cut and places a thin hollow tube (catheter) into a blood vessel in the patient's groin. The tube is advanced into the blood vessels in the neck and head. Dye is be injected into the tube several times and x-rays are taken to help view the blockage. The doctor try to remove the clot by putting a Health Canada approved device (eg. a stent retriever or other device) into the artery with the clot and removing the clot into the tube and pulling it out of the patient's body. Thrombectomy is a standard of care to the patients who have occlusion in the large vessel. However, we do not have data to help decide the doctors, if the same technique will work for certain medium vessel blockage or not. Currently there are smaller devices available, which are useful in accessing the medium size vessels and current study will gather information as to whether the thrombectomy treatment results in better outcome for the patients or not.

We are investigating the effectiveness of video-based apps in healthcare settings. We are looking for people to test these apps! Participants will receive $60 in Everything Card gift cards in appreciation of their time.

This study is looking at how shoe sole thickness may affect how you run. If you take part in this study, you will run on a treadmill at two speeds and in three shoes for 18 minutes total. Researchers will collect motion capture data as you run. The speeds are 3.0 m/s (5:30 min/km) and 3.6 m/s (4:40 min/km).

The aim of this study is to see if a 4 week treatment course of brain stimulation (transcranial magnetic stimulation; TMS) can improve attention and behaviour in children with attention deficit/hyperactivity disorder (ADHD). ADHD can have many symptoms with attention being a common problem. Stimulant treatment can improve attention in many children, but some only have partial improvement and others can't tolerate medications. A promising and alternative option for reducing ADHD symptoms is non-invasive brain stimulation. Transcranial magnetic stimulation (TMS) is a form of non-invasive brain stimulation that involves the application of a magnetic field to the skull to change the behaviour and function of underlying brain areas.

The purpose of this clinical research is to look at whether dupilumab works and how safe it is in adults with Chronic Obstructive Pulmonary Disease (COPD). If you choose and are eligible to take part, you will be in the study for a minimum of 26 weeks and up to 40 weeks. The study will consist of 3 parts: 1. Screening Period: 3 weeks period 2. Treatment Period: 24 weeks period 3. Follow-up period: 12 weeks follow-up period

This 52-week clinical study is sponsored by Newron Pharmaceuticals. The study aims to see how a drug called Evenamide works in people with schizophrenia whose symptoms have not improved enough with their current medication. Evenamide will be tested as an extra treatment added to the antipsychotic medicine you are already taking. The goal of this study is to find out if Evenamide is safe and if it can help improve symptoms when used together with standard antipsychotic drugs.

The purpose of this research study is to establish a wholistic SIDS registry in Alberta. We want to collect medical facts surrounding the death of the infant/child from the perspective of the parents whose child died suddenly and unexpectedly. The parents' perspective is incredibly valuable and our hope is that information gathered from this study will go on to help infants and families in the future.

To evaluate the effectiveness of a cannabis soft gel capsule compared to placebo as a preventative therapy for adult patients with chronic migraine. This is a randomized, double-blind, placebo-controlled clinical trial, with three arms: placebo, lower dose CBD, and higher dose CBD. Eligible study participants will undergo neurological assessment (history and physical exam), psychiatric assessment, and general medical assessment. Study participants will also undergo electrocardiograms, urinalysis, and blood work. Study participants will complete electronic headache diary, and questionnaire from baseline visit and throughout the study, and also complete study questionnaires at study visits (6 visits during 7 months).